STOCK TITAN
  1. Home
  2. Sec-filings
  3. DBHL
  4. [8-K] Deep Isolation Nuclear, Inc. Reports Material Event

Deep Isolation Nuclear (DBHL) widens Q2 loss amid demo investment

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Deep Isolation Nuclear, Inc., a developer of deep borehole nuclear waste disposal technology, reported second-quarter 2026 results while advancing key commercialization steps. The SEC declared its Form S-1 registration statement effective on May 7, 2026, enabling its common stock to be freely tradable, and the shares subsequently began trading on the OTCQB Venture Market under the ticker DBHL. The company surpassed 100 issued patents, established a permanent field presence at the Deep Borehole Demonstration Center in Texas for its full-scale, at-depth demonstration, and was selected as the sole industrial partner on three U.S. Department of Energy Project GENESIS grants.

For the three months ended June 30, 2026, revenue was $1,319 thousand, down 19% year over year, primarily due to completion of prior projects. Research and development expense rose to $1,180 thousand as the company ordered long-lead items and advanced engineering for its demonstration, while selling, general and administrative expenses increased to $2,746 thousand driven by higher professional fees and seven additional employees, including a Chief Financial Officer and General Counsel. Net loss widened to $(3,036) thousand (basic and diluted loss per share $(0.05)), with EBITDA of $(3,192) thousand and Adjusted EBITDA of $(1,915) thousand. As of June 30, 2026, cash totaled $19,379 thousand and total stockholders’ equity was $19,666 thousand, with 57,667,113 common shares outstanding as of August 3, 2026.

Positive

  • The SEC declared the company’s Form S-1 effective and its stock began trading on the OTCQB as DBHL, improving access to public capital and liquidity.
  • Participation as sole industrial partner on three DOE Project GENESIS grants and advancement in ARPA-E SCALEUP Ready contracting (potentially up to $20 million if successfully negotiated) strengthen its strategic and funding pipeline.

Negative

  • Quarterly net loss increased to $(3,036) thousand and six‑month net loss to $(8,452) thousand, while operating activities used $(8,044) thousand of cash in the first half of 2026.
  • Revenue declined 19% year over year to $1,319 thousand for Q2 2026, reflecting lower project activity following completion of certain contracts in 2025.

Filing Explained

Potential SCALEUP funding remains conditional while the filing reports second-quarter results.

This Form 8-K, whose Item 2.02 purpose is to report results of operations and financial condition, furnishes the company’s second-quarter results for the period ended June 30, 2026. The company says its SCALEUP Ready application remains in the contracting phase; if an award is successfully negotiated, it would provide up to $20 million toward field testing, so the filing discloses conditional funding capacity rather than committed proceeds.

That distinction means the release does not report that the SCALEUP award has been negotiated, received, or spent. The latest quarterly record shows March 31 cash of $22.226 million equaled 381.6 days of that quarter’s operating cash use of $5.242 million.

The named resolution point is completion of negotiations for the SCALEUP Ready award; the release does not state that the award has been finalized.

Sources and calculations
  • Cash and equivalents vs quarterly operating cash outflow, in days of cash use $22,226,000 / ($5,242,000 / 90) = [object Object]
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Revenue $1,319 thousand Three months ended June 30, 2026
Net loss $(3,036) thousand Three months ended June 30, 2026
Cash $19,379 thousand Cash balance as of June 30, 2026
Net cash used in operating activities $(8,044) thousand Six months ended June 30, 2026
EBITDA $(3,192) thousand Three months ended June 30, 2026
Adjusted EBITDA $(1,915) thousand Three months ended June 30, 2026
Total stockholders’ equity $19,666 thousand As of June 30, 2026
Adjusted EBITDA financial
"Adjusted EBITDA1 was $(1.9) million for the three months ended June 30, 2026"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
deep borehole disposal technical
"full-scale, at-depth demonstration of its DBD technologies for the deep borehole disposal of nuclear waste"
OTCQB Venture Market market
"the Company’s common stock began trading on the OTCQB Venture Market under the ticker symbol "DBHL""
The OTCQB Venture Market is a tier of the over‑the‑counter (OTC) trading platform that groups early‑stage, smaller companies that do not meet the stricter requirements of higher OTC tiers. It gives investors a way to buy and sell shares in these higher‑risk, less mature firms with generally lower reporting and transparency standards; think of it as a marketplace’s “starter lane” where potential is available but uncertainty and volatility are higher, so investors should expect greater risk and do extra homework.
Project GENESIS regulatory
"selected as the sole industrial partner on three U.S. Department of Energy Project GENESIS grants"
SCALEUP Ready program regulatory
"selected to participate in the SCALEUP Ready program, which, if an award is successfully negotiated"
Revenue $1,319 thousand Decreased from $1,634 thousand in the three months ended June 30, 2025.
Net loss $(3,036) thousand Widened from $(1,363) thousand in the three months ended June 30, 2025.
EBITDA $(3,192) thousand Declined from $(1,337) thousand in the three months ended June 30, 2025.
Adjusted EBITDA $(1,915) thousand Decreased from $(1,337) thousand in the three months ended June 30, 2025.
Cash $19,379 thousand Down from $27,434 thousand as of December 31, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were Deep Isolation Nuclear (DBHL)’s revenue and net loss for Q2 2026?
Deep Isolation Nuclear reported Q2 2026 revenue of $1,319 thousand and a net loss of $(3,036) thousand. Revenue fell about 19% from $1,634 thousand in Q2 2025, mainly as prior projects ended, while higher R&D and SG&A spending drove the larger loss.

How much cash did DBHL have as of June 30, 2026, and how is it changing?
As of June 30, 2026, Deep Isolation Nuclear held $19,379 thousand in cash. Cash declined from $27,434 thousand at December 31, 2025, largely because operating activities used $(8,044) thousand in the first half of 2026, reflecting increased R&D and operating costs.

What were DBHL’s EBITDA and Adjusted EBITDA for Q2 2026?
For Q2 2026, Deep Isolation Nuclear reported EBITDA of $(3,192) thousand and Adjusted EBITDA of $(1,915) thousand. Adjusted EBITDA excludes $97 thousand of registration statement expenses and $1,180 thousand of research and development related to its deep borehole demonstration program.

What operational milestones did Deep Isolation Nuclear (DBHL) achieve in Q2 2026?
During Q2 2026, Deep Isolation Nuclear surpassed 100 issued patents, established a permanent field presence at the Deep Borehole Demonstration Center in Texas, and continued preparing a full-scale, at-depth demonstration of its Universal Canister System and deep borehole disposal technology.

What capital markets steps did DBHL complete in 2026?
The SEC declared Deep Isolation Nuclear’s Form S-1 effective on May 7, 2026, making its common stock freely tradable. Subsequently, its shares were approved for quotation on the OTCQB Venture Market under the ticker symbol DBHL, with 57,667,113 shares outstanding as of August 3, 2026.

Which U.S. Department of Energy programs involve Deep Isolation Nuclear (DBHL)?
Deep Isolation Nuclear was selected as the sole industrial partner on three DOE Project GENESIS grants and is progressing through contracting for ARPA‑E’s SCALEUP Ready program, which, if an award is successfully negotiated, could provide up to $20 million for field testing.
2001 Addison StreetSuite 300BerkeleyCalifornia0001918080FALSE00019180802026-08-062026-08-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2026
Cover.jpg
DEEP ISOLATION NUCLEAR, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware000-5640687-4225965
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
2001 Addison Street, Suite 300
Berkeley, California
94704
(Address of Principal Executive Offices)(Zip Code)
(509)-943-5222
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, Deep Isolation Nuclear, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”) announcing its financial results for the second quarter ended June 30, 2026.
A copy of the Press Release referenced above is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “1934 Act”), nor shall it be deemed “incorporated by reference” into any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as may be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit NumberDescription
99.1
Press Release, dated August 6. 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DEEP ISOLATION NUCLEAR, INC.
Date: August 6, 2026
By:/s/ Rodney Baltzer
Rodney Baltzer
President and Chief Executive Officer





Exhibit 99.1
cover.jpg
FOR IMMEDIATE RELEASE
Deep Isolation Nuclear, Inc. Reports Operational and Financial Results for the Second Quarter of 2026


Operational Highlights for the Second Quarter of 2026

•The SEC declared Deep Isolation Nuclear, Inc.'s registration statement on Form S-1 effective on May 7, 2026, allowing the common stock of the Company to be freely tradable
•Surpassed 100 issued patents worldwide, spanning repository architecture, geologic site characterization, canister and packaging systems, emplacement and retrieval technologies, and repository closure and monitoring
•Established a full-time field presence at the Deep Borehole Demonstration Center near Cameron, Texas to lead execution of the Company's full-scale demonstration program
•Subsequent to quarter end, the Company's common stock began trading on the OTCQB Venture Market under the ticker symbol "DBHL"
•Subsequent to quarter end, on July 23, 2026 the Company was selected as the sole industrial partner on three competitive federal grants awarded under the U.S. Department of Energy's Project GENESIS program

Financial Highlights for the Second Quarter of 2026

•Reported consolidated revenue of $1.3 million
•Reported research and development expense of approximately $1.2 million related to the non-radioactive, full-scale, at-depth demonstration of our deep borehole waste disposal technology
•Had available cash of $19.4 million as of June 30, 2026
•Reported a net loss of $3.0 million primarily attributable to research and development and selling, general, and administrative expenses
•Total common shares outstanding as of August 3, 2026 of 57,667,113


BERKELEY, CA, August 6, 2026 – Deep Isolation Nuclear, Inc. (OTCQB: DBHL) (“Deep Isolation” or the “Company”), a leading innovator in nuclear waste disposal technology, today announced its operational and financial results for the three-months ended June 30, 2026.

“The second quarter was about converting milestones into execution,” said Rod Baltzer, CEO of Deep Isolation. “We established a permanent field presence at the Deep Borehole Demonstration Center near Cameron, Texas, to lead the world’s first full-scale, at-depth demonstration of deep borehole disposal, and we surpassed 100 issued patents worldwide — a portfolio that now spans the full disposal lifecycle, from geologic site characterization through canister emplacement and repository closure.

“We also took important steps as a public company. The SEC declared our registration statement on Form S-1 effective during the quarter, and shortly after quarter end our common stock began trading on the OTCQB Venture Market under the ticker symbol ‘DBHL.’ We were subsequently selected as the sole industrial partner on three Department of Energy Project GENESIS awards alongside Lawrence Berkeley National Laboratory and the University of South Carolina, deepening our research collaboration with the national laboratory system. These achievements demonstrate our team’s execution capabilities and reinforce Deep Isolation’s leadership in delivering practical solutions for one of the nuclear industry’s most critical challenges. We believe we are entering the market at exactly the right time, as the nuclear industry scales up and the need for a scalable waste disposal solution grows more urgent.”

Operational Progress

Deep Isolation advanced execution of its full-scale, at-depth deep borehole demonstration program at the Deep Borehole Demonstration Center (“DBDC”), located at Halliburton’s Drilling Technology Facility near Cameron, Texas. On June 17,





2026, the Company announced that Technology Demonstration Lead Jon Tedrick had relocated to Texas to establish a permanent field presence as the project moves toward active operations. Conducted via collaboration between the DBDC, Halliburton, Amentum, NAC International, Occlusion Nuclear Solutions and Westinghouse, the non-radioactive demonstration program is designed to demonstrate construction of a deep borehole repository using standard oil and gas drilling practices, full-scale emplacement and retrieval of the Company’s Universal Canister System (“UCS”), and simulated surface handling operations.

On May 27, 2026, the Company announced that it had surpassed 100 issued patents worldwide, spanning repository architecture, geologic site characterization, canister and packaging systems, emplacement and retrieval technologies, and repository closure and monitoring. Deep Isolation also continued to advance through the contracting phase for the U.S. Department of Energy's ("DOE) Advanced Research Projects Agency-Energy's ("ARPA-E") Seeding Critical Advances for Leading Energy technologies with Untapped Potential ("SCALEUP") Ready program, which, if an award is successfully negotiated, would provide up to $20 million toward full-scale field testing of the UCS at Cameron, Texas; Deep Isolation is the first company in the nuclear industry ever selected to participate in the SCALEUP Ready program.

Commercial Progress and Other Company Events

During the quarter, Deep Isolation completed the remaining steps required to make its common stock publicly tradable. On May 7, 2026, the U.S. Securities and Exchange Commission (“SEC”) declared the Company’s registration statement on Form S-1 effective, allowing the Company’s common stock to be freely tradable. The Company then worked with OTC Markets Group, Inc. on its application to have its shares of common stock quoted on the OTCQB Venture Market.

On July 13, 2026, the Company announced that its application for listing its common stock on the OTCQB Venture Market had been approved, and its common stock is now available to trade under the ticker symbol “DBHL.” On July 15, 2026, Chief Executive Officer Rod Baltzer issued a letter to shareholders marking the Company’s first quotation on the OTCQB and describing its transition from research and development toward commercial readiness.

On July 23, 2026, the Company was selected as the sole industrial partner on three U.S. Department of Energy Project GENESIS grants led by Lawrence Berkeley National Laboratory and the University of South Carolina, advancing artificial intelligence-enabled repository site screening, design and performance analysis.

Nuclear Industry Developments

The global nuclear energy industry continued to strengthen during the second quarter of 2026, supported by rising electricity demand, energy security priorities and the need for reliable, carbon-free generation. Governments and utilities continued advancing new reactor development and extending the operating lives of existing nuclear facilities, while growing electricity demand from artificial intelligence, data centers and industrial electrification accelerated corporate interest in nuclear power. Together, these trends reinforced the increasingly important role of nuclear energy in meeting long-term energy needs.

Government policy and financing also remained important catalysts for industry growth. During the quarter, the United States and several international governments advanced financing initiatives, licensing reforms and investment programs designed to accelerate deployment of both conventional and advanced nuclear technologies. Countries across North America and Europe continued expanding long-term nuclear generation plans, reflecting increasing recognition of nuclear energy as a strategic component of energy security and decarbonization efforts. Subsequent to quarter-end, the U.S. Department of Energy announced the first states selected to participate in its Nuclear Lifecycle Innovation Campuses initiative, highlighting continued federal investment in developing an integrated domestic nuclear fuel cycle and long-term spent fuel management infrastructure. This may have the potential to accelerate the need for borehole disposal options in the U.S.

Investment across the nuclear sector remained active throughout the quarter, with continued progress in advanced reactors, nuclear fuel, waste management and supporting infrastructure. In management's view, these developments reinforce the long-term outlook for nuclear energy and may increase demand for permanent nuclear waste disposal solutions as existing reactor fleets operate longer and new reactors enter service. These industry trends, if they continue, could strengthen the long-term market opportunity for Deep Isolation's technology and services.

















Financial Summary

(Amounts in thousands)For the Three Months Ended
6/30/20266/30/2025
Revenue$1,319 $1,634 
Research and development expense1,180—
Selling, general and administrative expenses2,7462,215
Net Loss(3,036)(1,363)
EBITDA1
(3,192)(1,337)
Adjusted EBITDA1
(1,915)(1,337)
Cash19,3791,852

Revenue decreased by approximately $0.3 million, or 19%, for the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The decrease in revenue was primarily attributable to lower revenues at Deep Isolation following the completion of certain projects during 2025.
Research and development expense increased by approximately $1.2 million for the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The increase in research and development expense was attributed to the ordering of long-lead items and front-end engineering work related to the Company's non-radioactive, full-scale, at-depth demonstration of its DBD technologies.
Selling, General and Administrative expenses increased by approximately $0.5 million, or 24%, for the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The increase in selling, general and administrative expenses was primarily attributable to higher accounting, audit, legal and travel expenses along with addition of 7 new employees since the beginning of 2026, including the Chief Financial Officer and General Counsel.
Net loss increased by $1.7 million for the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increases in research and development and selling, general and administrative expenses described above.
EBITDA1 was $(3.2) million for the three months ended June 30, 2026, compared to $(1.3) million for the three months ended June 30, 2025. The decrease in EBITDA was primarily attributed to higher research and development expenses and selling, general, and administrative expenses as described above.

Adjusted EBITDA1 was $(1.9) million for the three months ended June 30, 2026, compared to $(1.3) million for the three months ended June 30, 2025. The decrease in Adjusted EBITDA was primarily attributed to higher selling, general, and administrative expenses as described above.

1 EBITDA and Adjusted EBITDA are non-GAAP financial measures and should not be used in isolation or as a substitute for Deep Isolation’s financial results presented in accordance with Generally Accepted Accounting Principles ("GAAP"). For the definitions and reconciliations of these measures to the most directly comparable financial measures calculated and presented in accordance with GAAP, please refer to Exhibit II at the end of this press release


About Deep Isolation
Deep Isolation (OTCQB: DBHL) is the first company to undertake development of technologies for nuclear waste disposal in deep boreholes. When commercialized, Deep Isolation’s solution will offer a unique approach to help countries identify, plan for and complete the necessary steps to dispose of their nuclear waste inventories. With over 100 patents issued to date, Deep Isolation’s technology is being designed to leverage proven drilling practices to allow safe isolation of waste





deep underground in horizontal, vertical, or slanted borehole repositories. Deep Isolation’s Universal Canister System was developed through a three-year project funded by the U.S. Department of Energy’s Advanced Research Projects Agency–Energy and is engineered to support integrated management of spent fuel and high-level radioactive waste from legacy and advanced reactors across storage, transportation, and eventual disposal. In January 2026, Deep Isolation launched a full-scale, at-depth deep borehole Commercialization Pilot for its solution at Cameron, Texas, in collaboration with the Deep Borehole Demonstration Center, Halliburton (NYSE: HAL), Amentum (NYSE: AMTM), NAC International, and Occlusion Nuclear Solutions.

For more information, visit: deepisolation.com
Media Contact:
Sophie McCallum
media@deepisolation.com
Investor Contact:
Caldwell Bailey
ICR, Inc.
InvestorRelations@deepisolation.com
Forward-Looking Statements
Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding our plans, objectives and expectations for our business, the future growth of our business and the nuclear energy and nuclear waste disposal industries as a whole, and future benefits expected to arise from our strategic partnerships. In certain cases, forward-looking statements can be identified by the use of words and phrases or variations of words and phrases or statements such as “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions. Forward-looking statements are based on management’s belief and assumptions, including current expectations and projections about future events and trends, and on information currently available to management.
Forward-looking statements in this or any other news release are subject to a number of risks, uncertainties, and assumptions that could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Such risks, uncertainties, and assumptions are subject to a number of factors, including, among others: the failure of a market to develop for our deep borehole disposal solutions as quickly as we expect or at all; a failure of demand for our solution to develop sufficiently; regulatory and legal developments, including issues relating to obtaining regulatory approvals or permissions on the timelines we expect or at all; our lack of profitability; delays or failure in our initiative to complete a full-scale, at-depth demonstration of our Universal Canister System and our deep borehole solution; our failure to enter into contracts with customers or, once we do enter into contracts, to continue such contractual relationships or to receive new contract awards; our dependency on governmental contracts and awards and our ability to finalize negotiations on same; our failure to manage our growth effectively or to execute our business plan; our failure to sustain and expand relationships with governmental entities and strategic partners; a failure in the assumptions or analyses we have used in supporting forecasts or plans; our inability to commercialize our products at scale; the development or deployment of other technologies or solutions supplanting or competing with our technologies; challenges to our intellectual property; failures to protect, maintain, enforce, and enhance our intellectual property, and claims by others of intellectual property infringement; political and public perceptions of nuclear energy, including perceptions as to accidents or other high-profile events involving nuclear power facilities or radioactive materials; our liquidity and ability to raise capital; any inability to control operating and project costs and project delays or other project-related problems; security (including cybersecurity) breaches or disruptions; geopolitical, macroeconomic, domestic events or crises, including supply chain disruptions and other risks and uncertainties outside of our control; weather and effects of climate change; and litigation or legal proceedings that may be brought against us.

The foregoing is not an exhaustive list of all the factors that may cause any forward-looking statements to prove inaccurate or our actual results to differ materially from our expectations and forecasts. Moreover, we operate in a highly regulated environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this release may not occur and actual results





could differ materially and adversely from those anticipated or implied in the forward-looking statements, and we cannot guarantee future results, performance, or achievements. Accordingly, readers should not place undue reliance on forward-looking statements. We undertake no obligation to update any forward-looking statements for any reason after the date of this release or to conform these statements to actual results or revised expectations, except as required by law. Additional information concerning the factors above and other factors will be found in the Company’s public filings with the Securities and Exchange Commission (the “SEC”), including the sections titled “Forward-Looking Statements” and “Risk Factors” in the Company’s Reports on Form 10-K and 10-Q for the fiscal year ended December 31, 2025 and the quarter ending March 31, 2026, respectively, as filed with the SEC on March 30, 2026, our Form S-1, originally filed August 18, 2025 and subsequently amended, our Proxy Statement for our 2026 Annual Meeting as filed on April 29, 2026, and in filings with the SEC that will be made in the future.

The Company’s SEC filings are available free of charge at www.sec.gov or or upon written request to Deep Isolation at InvestorRelations@deepisolation.com or CorpSec@deepisolation.com.





Exhibit I - Unaudited Interim Financial Information

Deep Isolation Nuclear, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
June 30,
2026
(Unaudited)		December 31,
2025
Assets
Current assets:
Cash$19,379 $27,434 
Accounts receivable, net of allowance for credit losses of $124 and $118, respectively465 439 
Contract assets527 275 
Other current assets573 672 
Total current assets20,944 28,820 
Property, plant and equipment, net194 128 
Intangible assets, net33 73 
Finance lease right-of-use assets9 11 
Operating lease right-of-use assets209 269 
Goodwill182 182 
Other non-current assets$79 $140 
Total assets$21,650 $29,623 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$1,216 $1,113 
Accrued payroll290 774 
Contract liabilities— 150 
Finance lease liabilities, current3 3 
Operating lease liabilities, current132 125 
Other current liabilities252 101 
Total current liabilities1,893 2,266 
Finance lease liabilities, net of current portion7 9 
Operating lease liabilities, net of current portion84 152 
Total liabilities1,984 2,427 
Commitments and Contingencies (Note 16)
Stockholders’ Equity
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 57,647,613 and 57,542,113 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively6 6 
Additional paid-in capital60,345 59,456 
Accumulated deficit(40,955)(32,503)
Accumulated other comprehensive income270 237 
Total stockholders’ equity19,666 27,196 
Total liabilities and stockholders’ equity$21,650 $29,623 







Deep Isolation Nuclear, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited) (in thousands, except share and per share data)
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Revenue$1,319 $1,634 $2,766 $3,154 
Cost of services (exclusive of depreciation shown separately below)(612)(756)(1,293)(1,418)
Gross profit707 878 1,473 1,736 
Operating expenses:
Selling, general and administrative expenses2,746 2,215 5,586 3,208 
Research and development1,180 — 4,669 — 
Depreciation and amortization expense25 30 50 59 
Total operating expenses3,951 2,245 10,305 3,267 
Loss from operations(3,244)(1,367)(8,832)(1,531)
Gain on insurance settlement27 — 27 — 
Other income181 4 353 3 
Net loss before income taxes(3,036)(1,363)(8,452)(1,528)
Provision for income taxes— — — 1 
Net loss$(3,036)$(1,363)$(8,452)$(1,529)
Other comprehensive income (loss):
Foreign currency translation adjustments(15)9 33 (40)
Total other comprehensive income (loss)(15)9 33 (40)
Other comprehensive loss$(3,051)$(1,354)$(8,419)$(1,569)
Net loss per common share – basic and diluted$(0.05)$(0.03)$(0.15)$(0.04)
Weighted average common shares outstanding - basic and diluted57,660,684 42,151,949 57,684,662 41,447,903 







Deep Isolation Nuclear, Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited) (in thousands, except share and per share data)

Common Stock
Preferred Stock
Series A
Preferred Stock Series
A Prime
Additional
Paid in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Income
Total
Stockholders’
Equity
Shares AmountShares AmountShares Amount
Balance, January 1, 2025773,941$— 655,351$— 115,057$— $29,962 $(27,167)$122 $2,917 
Retroactive application of Merger39,127,8384 (655,351)— (115,057)— (4)— — — 
Adjusted Balance beginning of quarter39,901,779$4 —$— —$— $29,958 $(27,167)$122 $2,917 
Exercise of stock options1,330,620— —— —— 70 — — 70 
Stock based compensation—— —— —— 25 — — 25 
Foreign currency translation adjustments—— —— —— — — (50)(50)
Net loss—— — — — — — (166)— (166)
Balance, March 31, 202541,232,3994————30,053(27,333)722,796
Exercise of stock options2,737,355— —— —— 324 — — 324 
Stock based compensation—— —— —— 30 — — 30 
Foreign currency translation adjustments—— —— —— — — 9 9 
Net loss—— —— —— — (1,363)— (1,363)
Balance, June 30, 202543,969,754$4 —$— —$— $30,407 $(28,696)$81 $1,796 
Balance, January 1, 202657,542,113$6 —$— —$— $59,456 $(32,503)$237 $27,196 
Exercise of stock options and distribution of restricted stock units105,500— —— —— 4 — — 4 
Stock based compensation—— —— —— 522 — — 522 
Foreign currency translation adjustments—— —— —— — — 48 48 
Net loss—— —— —— — (5,416)— (5,416)
Balance, March 31, 202657,647,6136————59,982(37,919)285$22,354 
Exercise of stock options and distribution of restricted stock units19,500— —— —— — — — — 
Stock based compensation—— —— —— 363 — — 363 
Foreign currency translation adjustments—— —— —— — — (15)(15)
Net loss—— —— —— — (3,036)— (3,036)
Balance, June 30, 202657,667,113$6 —$— —$— $60,345 $(40,955)$270 $19,666 






Deep Isolation Nuclear, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited) (in thousands, except share and per share data)
Six Months Ended
June 30,
20262025
Cash Flows from Operating Activities:
Net loss$(8,452)$(1,529)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense50 59 
Interest expense1 1 
Stock based compensation885 55 
   Gain on insurance settlement(27)—
Changes in operating assets and liabilities:
Accounts receivable(32)313 
Allowance for credit losses6 12 
Contract assets(252)(57)
Other current assets99 44 
Other non current assets61 — 
Account payable103 198 
Contract liabilities(150)— 
Accrued expenses(484)(125)
Other current liabilities146 410 
Operating lease right-of-use assets and lease liabilities2 1 
Net cash used in operating activities(8,044)(618)
Cash Flows from Investing Activities:
Purchases of property, plant and equipment(74)(31)
Proceeds from insurance on disposal of fixed asset27 — 
Net cash used in investing activities(47)(31)
Cash Flows from Financing Activities:
Payment of finance lease liability(1)(2)
Proceeds from exercise of stock options4 394 
Net cash provided by financing activities3 392 
Net change in cash and cash equivalents(8,088)(257)
Effect of exchange rate on cash and cash equivalents33 (40)
Cash and cash equivalents:
Beginning of period27,434 2,149 
End of period$19,379 $1,852 
Supplemental schedule of non-cash investing and financing activities:











Exhibit II Non-GAAP Financial Measures: EBITDA and Adjusted EBITDA

EBITDA is defined as earnings before depreciation, amortization, finance income and expense, and taxes. Adjusted EBITDA is defined as EBITDA before certain items, including registration statement expenses and research and development expenses, that management believes are not indicative of core ongoing operations for the periods presented. EBITDA and Adjusted EBITDA are non-GAAP financial measures that are used as supplemental financial measures by management and external users of financial statements, such as investors, to assess our financial and operating performance. We believe that these non-GAAP financial measures assist our management and investors by increasing the comparability of our performance from period to period. We believe that including EBITDA and Adjusted EBITDA assists our management and investors in (i) understanding and analyzing the results of our operating and business performance, (ii) selecting between investing in us and other investment alternatives and (iii) monitoring our ongoing financial and operational strength in assessing whether to purchase and/or to continue to hold our common shares. This is achieved by excluding the potentially disparate effects between periods of, in the case of EBITDA and Adjusted EBITDA, financial income and expenses,, taxes, depreciation and amortization; in the case of Adjusted EBITDA, registration statement expenses and research and development expenses, which are excluded because they relate to specific, discrete initiatives and may vary significantly based on the timing and scope of such activities.

EBITDA and Adjusted EBITDA have limitations as analytical tools and should not be considered as alternatives to, or as substitutes for, or superior to, profit or loss, profit or loss from operations, earnings or loss per share or any other measure of operating performance presented in accordance with GAAP. Some of these limitations include the fact that they do not reflect (i) our cash expenditures or future requirements for capital expenditures or contractual commitments and (ii) changes in, or cash requirements for, our working capital needs. Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements. EBITDA and Adjusted EBITDA are not adjusted for all non-cash income or expense items that are reflected in our statements of cash flows and other companies in our industry may calculate these measures differently than we do, limiting their usefulness as a comparative measure.

In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as, or similar to, some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by the excluded items. Therefore, the non-GAAP financial measures as presented below may not be comparable to similarly titled measures of other companies in the nuclear or other industries.

The following table presents a reconciliation of net loss to EBITDA and Adjusted EBITDA for each of the periods presented (in thousands):

For the Three Months Ended
June 30, 2026June 30, 2025
Net loss$(3,036)$(1,363)
Depreciation and amortization expense2530
Other income (expense)(181)(4)
Provision for income taxes——
EBITDA(3,192)(1,337)
Registration statement expenses (1)97—
Research and development expenses (2)1,180—
Adjusted EBITDA$(1,915)$(1,337)

(1) Represents specific costs that are incremental and discrete to the periods presented and are not indicative of our core ongoing operations. For the three months ended June 30, 2026, these amounts were comprised of non-routine legal costs associated with the Company's registration statement that do not qualify for equity issuance costs and outside the ordinary course of business.
(2) For the three months ended June 30, 2026, these amounts were comprised of research and development costs incurred to design, develop, test, and validate the Company’s technologies and services for the deep borehole disposal of nuclear waste. The Company believes excluding these investments provides investors with additional insight into the operating





performance of its core business activities and enhances comparability across reporting periods by removing costs that may vary significantly based on the timing and scope of development initiatives.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents